—A recent study provides genetic evidence linking a higher body mass index (BMI) to an increased risk of primary biliary cholangitis and autoimmune hepatitis but a decreased risk of primary sclerosing ...
Researchers provide the most comprehensive genetic synopsis of primary biliary cholangitis to date, identifying 44 risk-associated variants with strong evidence for novel genome-wide significant loci.
Phase II ELMWOOD trial shows elafibranor is well tolerated and improves liver biochemistry and pruritus in primary sclerosing ...
Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease of uncertain etiology characterized by the destruction of the intrahepatic and/or extrahepatic ducts through ...
Please provide your email address to receive an email when new articles are posted on . Interim analyses of two phase 2b studies of volixibat support its use as potential treatment for patients with ...
EXTON, PA, July 17, 2025 (GLOBE NEWSWIRE) -- The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked transformation over the past year, driven by the recent approvals of ...
A Prescription Drug User Fee Act target date of August 14, 2024 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...
Findings showed a statistically significantly greater proportion of saroglitazar-treated patients achieved a biochemical response vs placebo (treatment difference, 48.5%; P .001). Topline data were ...
Your doctor may recommend a combination of medications, dietary supplements, and lifestyle changes to help manage primary biliary cholangitis (PBC). Some people eventually need a liver transplant to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback